About
FineImmune Biotechnology develops T cell therapies targeting technical challenges in the tumor microenvironment and has identified proprietary biomarkers such as CXCL13 to enable anti-cancer therapies including TAL, personalized TCRT, and CART.
Explore FineImmune Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.